Ardelyx (ARDX) Q3 2026 Earnings Call Transcript
Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.
How this was made

The 30-second read
Why it matters
The earnings data offers fresh insight into Ardelyx's financial health and may prompt short‑term trading adjustments.
Market read
First‑time earnings disclosure for Q3 2026, material for traders tracking biotech earnings.
What to watch
Potential upcoming regulatory decisions on IBSRELA could outweigh the earnings impact.
Background
Ardelyx provided its Q3 2026 earnings call, highlighting revenue growth, loss narrowing, and cash balance.
Ticker impact
Q3 2026 earnings call disclosed total product revenue $125.5M, net loss $0.7M, cash $285.3M and reaffirmed full-year guidance.
likely modest upside as the market prices in the narrowed loss and reaffirmed guidance
The company reported better-than-expected loss reduction and solid cash, which typically supports a short-term price lift.
Market effects
Biotech earnings season may influence peer valuations, especially other gut‑microbiome players.
U.S. biotech sector sees slight positive pressure.
Limited to investors tracking U.S. biotech earnings.
Counterpoint
If the market had already priced in the guidance reaffirmation, the earnings may not move the stock significantly.
Key entities
- companyArdelyx
U.S. biotech firm focused on kidney disease therapies.

